Sign in
CompletedNo phase

Calcifediol in the Treatment of SARS-CoV-2 Disease (COVID-19).

Key facts

Who runs it
Complejo Hospitalario Universitario de Albacete
Where
Spain1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
230 people enrolled
Started
21 Feb 2024
Ended
25 Apr 2024
Type of study
Observational, 2 groups
Treatments tested
  • Calcifediol
Record updated
5 June 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (6)Hide the full registry criteria

Who can take part

  • Admitted to the hospital CHUA
  • Meet the SARS-CoV-2 diagnostic criteria with positive PCR
  • They have completed at least the first dose of Calcifediol within the first 72 hours after admission, (according to protocol)

Who cannot take part

  • Patients with other serious intercurrent diseases (eg advanced oncological pathology)
  • Patients who do not receive the full first dose of Calcifediol within the first 72 hours
  • Patients for whom electronic medical record data cannot be collected

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Descriptive, retrospective, observational, anonymous, study to evaluate the potential effect of incorporating calcifediol into the therapeutic protocol of patients hospitalized for COVID-19 on mortality and other outcome variables, such as admission to the Intensive Care Unit (ICU), to "Complejo Hospitalario Universitario de Albacete" (CHUA). Albacete (Spain)", based on the files of the MXXI medical records, Information System of the Laboratory (ISL) and Pharmacy.

The 2 groups in the trial

  • Patients treated with calcifediol

    Patients admitted to the CHUA, due to COVID-19 \[respiratory infection confirmed by radiographic pattern of viral pneumonia and positive polymerase chain reaction (PCR)/antigen for SARS-CoV-2\] treated with calcifediol

    Treatment: Calcifediol

  • Patients not treated with calcifediol

    Patients admitted to the CHUA, due to COVID-19 (respiratory infection confirmed by radiographic pattern of viral pneumonia and positive PCR/antigen for SARS-CoV-2) not treated with calcifediol

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Inclusion of Calcifediol in the Hospital Therapeutic Protocol for Treatment of SARS-CoV-2 Disease (COVID-19). Mortality Analysis. Retrospective Study.
Record updated
5 June 2025